文献速递胸部肿瘤

小细胞肺癌患者游离DNA纵向分析揭示疗效与疾病复发动态

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
PubMed 文献 · J Thorac Oncol · 2017-09-23

本研究开发了一种检测14个常突变基因的游离DNA液体活检方法,在26个月内对27例小细胞肺癌患者的140份血浆样本进行分析,85%的样本检出疾病相关突变,等位基因频率和拷贝数变化与治疗反应密切相关,部分病例中cfDNA早于常规影像提示疾病复发。

要点

  • 在27例小细胞肺癌患者的140份血浆样本中,85%检出疾病相关突变,突变等位基因频率范围为0.1%至87%。
  • 队列中59%的患者为广泛期疾病,最常见突变为TP53(70%)和RB1(52%)。
  • 观察到的等位基因频率和拷贝数变化与治疗反应密切相关,部分病例中cfDNA早于常规影像提示疾病复发。

核心结论

  • 液体活检在小细胞肺癌患者中易于应用,可能有助于改善疾病负荷监测、治疗反应深度评估和疾病复发的及时预警。

研究设计与样本

  • 研究开发了一种量化血浆游离DNA体细胞变异的液体活检方法,检测14个在小细胞肺癌中常突变基因的单核苷酸变异、拷贝数改变和插入或缺失。
  • 在26个月的外周血采集过程中, examined 27例患者的140份血浆样本。

主要发现

  • 85%的患者样本检出疾病相关突变,突变等位基因频率范围为0.1%至87%。
  • 队列中59%的患者为广泛期疾病,最常见突变为TP53(70%)和RB1(52%)。
  • 除TP53和RB1突变外,在患者群体中还检测到另外10个基因的改变(PTEN、NOTCH1、NOTCH2、NOTCH3、NOTCH4、MYC、MYCL1、PIK3CA、KIT和BRAF)。
  • 观察到的等位基因频率和拷贝数改变与治疗反应密切相关。
  • 在几个病例中,cfDNA分析在常规影像之前提供了疾病复发的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with SCLC have a poor prognosis and limited treatment options. Because access to longitudinal tumor samples is very limited in patients with this disease, we chose to focus our studies on the characterization of plasma cell-free DNA (cfDNA) for rapid, noninvasive monitoring of disease burden. METHODS: We developed a liquid biopsy assay that quantifies somatic variants in cfDNA. The assay detects single nucleotide variants, copy number alterations, and insertions or deletions in 14 genes that are frequently mutated in SCLC, including tumor protein p53 gene (TP53), retinoblastoma 1 gene (RB1), BRAF, KIT proto-oncogene receptor tyrosine kinase gene (KIT), notch 1 gene (NOTCH1), notch 2 gene (NOTCH2), notch 3 gene (NOTCH3), notch 4 gene (NOTCH4), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), phosphatase and tensin homolog gene (PTEN), fibroblast growth factor receptor 1 gene (FGFR1), v-myc avian myelocytomatosis viral oncogene homolog gene (MYC), v-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog gene (MYCL1), and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog gene (MYCN). RESULTS: Over the course of 26 months of peripheral blood collection, we examined 140 plasma samples from 27 patients. We detected disease-associated mutations in 85% of patient samples with mutant allele frequencies ranging from 0.1% to 87%. In our cohort, 59% of the patients had extensive-stage disease, and the most common mutations occurred in TP53 (70%) and RB1 (52%). In addition to mutations in TP53 and RB1, we detected alterations in 10 additional genes in our patient population (PTEN, NOTCH1, NOTCH2, NOTCH3, NOTCH4, MYC, MYCL1, PIK3CA, KIT, and BRAF). The observed allele frequencies and copy number alterations tracked closely with treatment responses. Notably, in several cases analysis of cfDNA provided evidence of disease relapse before conventional imaging. CONCLUSIONS: These results suggest that liquid biopsies are readily applicable in patients with SCLC and can potentially provide improved monitoring of disease burden, depth of response to treatment, and timely warning of disease relapse in patients with this disease.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Almodovar K, Iams WT, Meador CB, et al. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol. 2017. PMID: 28951314. doi:10.1016/j.jtho.2017.09.1951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。